- Home/
- Article

| 4 min read
A cascade of high-profile drug recalls and evolving FDA and EMA guidance have pushed nitrosamine risk assessment from a late-stage afterthought to an early-development priority


Stay connected with all of the latest from Drug Discovery News.
Subscribe